RESEARCH REACHES SIGNIFICANT MILESTONE IN DEVELOPMENT OF F-18 PIB FOR BRAIN AMYLOID IMAGING

Main Menu | News By Date | News By Supplier | News By Category | About Us

RESEARCH REACHES SIGNIFICANT MILESTONE IN DEVELOPMENT OF F-18 PIB FOR BRAIN AMYLOID IMAGING
17 January 2006 - AZDEL

A key milestone in the imaging of Alzheimer’s Disease has been reached through a close collaboration between radiochemists from the University of Pittsburgh and GE Healthcare. The University of Pittsburgh has started a study aimed at obtaining preliminary information on the performance of flourine-18 labelled Pittsburgh Compound B (F-18 PiB) to identify amyloid deposits in subjects with a diagnosis of AD. Chet Mathis, Professor Of Radiology, University of Pittsburgh School of Medicine and director of the PET Facility at UPMC reports, "early results are encouraging and we look forward to the larger multi-site trials that GE Healthcare will perform with F-18 PiB in early 2007."

The imaging of brain amyloid by carbon-11 PiB has been judged by Nature Medicine to be one of the most significant advances in the field of AD in recent years. Multiple sites have now replicated the landmark studies reported by Klunk et al in Annals of Neurology. More recently the U.S.-based Alzheimer’s Association and GEHC have funded a C-11 PIB add-on study to the Alzheimer’s Disease Neuroimaging Initiative, a $60M study to determine the value of brain imaging.

Although C-11 PiB can be used for academic studies, the 20-minute half-life of C-11 and limited manufacturing access means the molecule is not suitable for widespread use as a routine diagnostic agent. F-18, with a half-life of 110 minutes, offers a much better opportunity for manufacturing and distribution.

In 2003, GE Healthcare licensed a number of compounds from the University of Pittsburgh. Proof of concept studies have already been performed in collaboration with GE Healthcare’s IMANET organization, leading to the selection of the lead candidate for further research. Subsequent work has focused on producing the F-18 PiB material to the quality standards necessary for clinical trial use. Don Black, Head of R&D, Medical Diagnostics commented, "good progress is being made with the set up of the PET centres for the forthcoming trial. Recent news from the University of Pittsburgh about the first subjects injected with F-18 PIB is cause for optimism in the potential use of this agent as a future tool for both diagnosis and therapy monitoring."

Kim Gallagher, the newly appointed Head of External Affairs, R&D, Medical Diagnostics also remarked, "these are exciting times in the field of Alzheimer’s Disease. The advent of amyloid imaging agents and the wealth of pharma programs in the area of amyloid targeted therapies, have given real hope that significant progress, in the notoriously slow field of dementia, can be made in the next decade.”

http://www.ge.com

About: AZDEL
AZDEL, Inc. is a joint venture of GE Advanced Materials and PPG Industries. The AZDEL business was established in 1972 by PPG, and the 50/50 joint venture was set up with GE in 1986. AZDEL is a global leader in the manufacture and supply of high-performance composite materials serving a wide variety of markets and industries including automotive, transportation interiors, large truck, materials handling, heating, ventilation and air conditioning (HVAC), and building and construction.

* AZDEL and VolcaLite are trademarks of AZDEL, Inc., a 50/50 joint venture of General Electric Company and PPG Industries.

More News:
  • For January 2006
  • From AZDEL
  • For Thermoplastic Composites